Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers

Pathology International

Volumn 59, Issue 3, 2009, Pages 161-166

  Ishikawa, Kiyoshi ^b   Segawa, Tatsuya ^b   Hagiwara, Yoshiaki ^a,b   Maeda, Masahiro ^b   Abe, Masaaki ^a   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Diagnosis; ERC mesothelin; Malignant mesothelioma; Monoclonal antibody

Indexed keywords

HYBRID PROTEIN; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 22A31; MONOCLONAL ANTIBODY 5B2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SELECTION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 60649101905     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02344.x     Document Type: Article

References (13)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005 366 : 397 408.
2. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999 117 : 54 63.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant mesothelioma. J Clin Oncol 2003 21 : 2636 44.
4. Sugarbaker DJ, Jaklitsch MT, Bureno R et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004 128 : 138 46.
5. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnosis markers. Pathol Int 2006 56 : 649 54.
6. Shiomi K, Miyamoto H, Segawa T et al. A novel ELISA system for detection of a N-ERC/Mesothelin in the sera of mesothelioma patients. Cancer Sci 2006 97 : 928 32.
7. Hino O, Shiomi K, Maeda M. Diagnostic biomarkers of asbestos-related mesothelioma: Example of translational research. Cancer Sci 2007 98 : 1147 51.
8. Hino O, Kobayashi E, Nishizawa M et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995 121 : 602 5.
9. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000 275 : 134 40.
10. Hino O. Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med 2004 4 : 807 11.
11. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Ras 2004 10 : 3937 42.
12. Hassan R, Remaley AT, Sampson ML et al. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006 12 : 447 53.
13. Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006 97 : 387 94.